6. Parkinson disease Clinical trials / Disease details
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00163085 (ClinicalTrials.gov) | May 2005 | 9/9/2005 | The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease | A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Explore The Efficacy And Safety Of The NR2B NMDA Antagonist CP-101,606 In Patients With Idiopathic Parkinson's Disease | Parkinson's Disease | Drug: NR2B NMDA Antagonist CP-101,606 (traxoprodil) | Pfizer | NULL | Completed | 30 Years | 80 Years | Both | 12 | Phase 2 | United States |